Effect of pentoxifylline on survival and intestinal cytokine messenger RNA transcription in a rat model of ongoing peritoneal sepsis

Critical Care Medicine

Volumn 27, Issue 1, 1999, Pages 113-119

  Nelson, Jeffrey L ^b   Alexander, J Wesley ^a,b,c   Mao, Ju Xian ^a   Vohs, Tania ^b   Ogle, Cora K ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b SHRINERS HOSPITALS FOR CHILDREN   (United States)

^c Department of Surgery ^*  (United States)

Author keywords

Cytokines; Enteral diets; Immunonutrition; Interleukins; Intestinal function; Lipopolysaccharide; Pentoxifylline; Peritonitis; Sepsis; Translocation

Indexed keywords

CYTOKINE; INTERLEUKIN 6; MESSENGER RNA; PENTOXIFYLLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL PERITONITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; ENTERIC FEEDING; GASTROSTOMY; INFLAMMATION; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; RAT; RNA TRANSCRIPTION; SEPSIS; SURVIVAL RATE;

ANIMALS; BACTEREMIA; CRITICAL CARE; CYTOKINES; DIETARY PROTEINS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INTESTINES; LIVER; MALE; PENTOXIFYLLINE; PERITONITIS; PHOSPHODIESTERASE INHIBITORS; PROSPECTIVE STUDIES; RANDOM ALLOCATION; RATS; RATS, INBRED LEW; RNA, MESSENGER; SURVIVAL ANALYSIS; TRANSCRIPTION, GENETIC;

EID: 0032952918     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199901000-00038     Document Type: Article

References (44)

1. 1. Gennari R, Alexander JW, Eaves-Pyles T: Effect of different combinations of dietary additives on bacterial translocation and survival in gut-derived sepsis. JPEN 1995; 19:319-325
2. 2. Gottschlich MM, Jenkins M, Warden GD, et al: Differential effects of three enteral dietary regimens on selected outcome variables in burn patients. JPEN 1990; 14:225-236
3. 3. Daly JM, Weintraub FN, Shou J, et al: Enteral nutrition during multimodality therapy in upper gastrointestinal cancer patients. Ann Surg 1995; 221: 327-338
4. 4. Moore FA, Moore EE, Kudsk KA, et al: Clinical benefits of an immune-enhancing diet for early postinjury enteral feeding. J Trauma 1994; 37:607-615
5. 5. Bower RH, Cerra FB, Bershadsky B, et al: Early enteral administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care patients: Results of a multicenter, prospective, randomized, clinical trial. Crit Care Med 1995; 23:436-449
6. 6. Kemen M: European multicenter study in postoperative cancer patients. J Crit Care Nutr 1995; 3:22-23
7. 7. Daly JM, Lieberman MD, Goldfine J, et al: Enteral nutrition with supplemental arginine, RNA, and omega-3 fatty acids in patients after operation: Immunologic, metabolic, and clinical outcome. Surg 1992; 112:56-67
8. 8. Kudsk KA, Minard G, Croce MA, et al: A randomized trial of isonitrogenous enteral diets following severe trauma. An immune-enhancing diet (IED) reduces septic complications. Ann Surg 1996; 224:531-540
9. 9. Alexander JW, Gonce SJ, Miskell PW, et al: A new model for studying nutrition in peritonitis. The adverse effect of overfeeding. Ann Surg 1989 209: 334-340
10. 10. Peck MD, Alexander JW, Gonce SJ, et al: Low protein diets improve survival from peritonitis in guinea pigs. Ann Surg 1989; 209:448-454
11. 11. Nelson JL, Alexander JW, Gianotti L, et al: High protein diets are associated with increased bacterial translocation in septic guinea pigs. Nutrition 1996; 12:195-199
12. 12. Thijs LG, Hack CE: Time course of cytokine levels in sepsis. Intensive Care Med 1995; 21:S258-S263
13. 13. Pinsky MR, Vincent JL, Deviere J, et al: Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993; 103:565-575
14. 14. Ayala A, Ertel W, Chaudry IH: Trauma-induced suppression of antigen presentation and expression of major histo-compatibility class II antigen complex in leukocytes. Shock 1996; 5:79-90
15. 15. Ayala A, Deol ZK, Lehman DL, et al: Polymicrobial sepsis but not low dose endotoxin infusion causes decreased splenocyte IL-2/IFN gamma release while increasing IL-4/IL-10 production. J Surg Res 1994; 56:579-585
16. 16. Ertel W, Scholl F, Steckholzer U, et al: Interleukin-10 attenuates the release of proinflammatory cytokines but depresses splenocyte functions in murine endotoxemia sepsis. Arch Surg 1996; 131:51-56
17. 17. Kehrl JH, Wakefield LM, Roberts AB, et al: Production of transforming growth factor-β by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986; 163:1037-1050
18. 18. Ranges GE, Figari IS, Espevik T, et al: Inhibition of cytotoxic T-cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor α. J Exp Med 1987; 166:991-998
19. 19. Rook AH, Kehrl JH, Wakefield LM, et al: Effects of transforming growth factor β on the function of natural killer cells: Depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 1986; 136:3916-3920
20. 20. Espevik T, Figari IS, Refaat Shalaby M, et al: Inhibition of cytokine production by cyclosporin A and transforming growth factor β. J Exp Med 1987; 166:571-576
21. 21. Geller DA, Kispert PH, Su GL, et al: Induction of hepatocyte lipopolysaccharide binding protein in models of sepsis and the acute-phase response. Arch Surg 1993; 128:22-27
22. 22. Froon AH, Dentener MA, Greve JW, et al: Lipopolysaccharide toxicity-regulating proteins in bacteremia. J Infect Dis 1995 171:1250-1257
23. 23. Ogle CK, Guo Xialing, Hasselgren PO, et al: The gut as a source of inflammatory cytokines after stimulation with endotoxin. Eur J Surg 1997; 163: 45-51
24. 24. Deitch EA, Dazhong X, Franko L, et al: Evidence favoring the role of the gut as a cytokine-generating organ in rats subjected to hemorrhagic shock. Shock 1994; 1:141-146
25. 2 by isolated enterocytes and gut macrophages - Effects of lipopolysaccharide and thermal injury. J Burn Care Rehabil 1994; 15:470-477
26. 26. Alexander JW, Ogle CK, Nelson JL: Diets and infection: Composition and consequences. World J Surg 1998; 22:209-212
27. 27. Tighe D, Moss R, Hynd J, et al: Pretreatment with pentoxifylline improves the hemodynamic and histologic changes and decreases neutrophil adhesiveness in a pig fecal peritonitis model. Crit Care Med 1990; 18:184-189
28. 28. Tighe D, Moss R, Heath MF, et al: Pentoxifylline reduces pulmonary leucostasis and improves capillary patency in a rabbit peritonitis model. Circ Shock 1989; 28:159-164
29. 29. Schade UF, Von der Bosch J, Schonharting M: Pentoxifylline increases survival of mice in endotoxin shock. Prog Clin Biol Res 1989; 301:223-227
30. 30. Holzheimer RG, Molloy RG, Riordain DS, et al: Long-term immunotherapeutic intervention with pentoxifylline in a mouse model of thermal injury and infection. J Trauma 1995; 38:757-762
31. 31. Dominioni L, Stinnett JD, Fang CH, et al: Gastrostomy feeding in normal and hypermetabolic burned guinea pigs: A model for the study of enteral diets. J Burn Care Rehabil 1984; 5:100-105
32. 32. Schade UF: Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. Circ Shock 1990; 31:171-181
33. 33. Hadjiminas DJ, McMasters KM, Robertson SE, et al: Enhanced survival from cecal ligation and puncture with pentoxifylline is associated with altered neutrophil trafficking and reduced interleukin-1β expression but not inhibition of tumor necrosis factor synthesis. Surg 1994; 116:348-355
34. 34. Bjornson HS, Cave CM, Bjornson AB: Effects of pentoxifylline on survival and chemotaxis of polymorphonuclear leukocytes in a rat model of bacterial peritonitis. In: Pentoxifylline and Leukocyte Function. Mandell GL, Novick WJ Jr, (Eds). Somerville, NJ, Hoechst-Roussel Pharmaceuticals, 1988, pp 138-153
35. 35. Josaki K, Contrino J, Kristie J, et al: Pentoxifylline-induced modulation of human leukocyte function in vitro. Am J Pathol 1990; 136:623-630
36. 36. Crabtree JE, Shallcross TM, Heatley RV, et al: Mucosal tumour necrosis factor a and interleukin-6 in patients with Helicobacter pylori associated gastritis. Gut 1991; 32:1473-1477
37. 37. Mahida YR, Kurlac L, Gallagher A, et al: High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis. Gut 1991; 32:1531-1534
38. 38. McGee DW, Beagley KW, Aicher WK, et al: Transforming growth factor-β enhances interleukin-6 secretion by intestinal epithelial cells. J Immunol 1992; 77:7-12
39. 39. McGee DW, Beagley KW, Aicher WK, et al: Transforming growth factor-β and IL-1β act in synergy to enhance IL-6 secretion by the intestinal epithelial cell line, IEC-61. J Immunol 1993; 151:970-978
40. 40. Mitsuyama K, Sasaki E, Toyonaga H, et al: Colonic mucosal interleukin-6 in inflammatory bowel disease. Digestion 1991; 50:104-111
41. 41. Shirota K, LeDuy L, Yuan S, et al: Interleukin-6 and its receptor are expressed in human intestinal epithelial cells. Virchows Arch B Cell Pathol 1990; 58:303-308
42. 42. Mester M, Tompkins RG, Gelfand JA, et al: Intestinal production of interleukin-1 α during endotoxemia in the mouse. J Surg Res 1993; 54:584-591
43. 2. Arch Surg 1994; 129:1290-1294
44. 44. Meyer TA, Tiao GM, James JH, et al: Nitric oxide inhibits LPS-induced IL-6 production in enterocytes. J Surg Res 1995; 58:570-575